|Table of Contents|

Research progress of extranodal NK/T cell lymphoma in radiotherapy and chemotherapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 01
Page:
132-136
Research Field:
Publishing date:

Info

Title:
Research progress of extranodal NK/T cell lymphoma in radiotherapy and chemotherapy
Author(s):
Zhang Qi; Jiang Hao; Zhou Yongchun
Department of Radiation Oncology，the First Affiliated Hospital of Bengbu Medical College，Anhui Bengbu 233004，China.
Keywords:
extranodal nasal NK/T-cell lymphoma; radiotherapy; chemotherapy
PACS:
R730.53；R730.55
DOI:
10.3969/j.issn.1672-4992.2018.01.035
Abstract:
Extranodal NK/T-cell lymphoma，nasal type （ENKTL) is a special type of non-Hodgkin's lymphoma.Because of low incidence，most of current clinical treatment evidences are from retrospective analysis or phase II clinical trials of small samples.Due to lack of large randomized controlled trials，treatment criteria for this disease have not been set up.Radiotherapy and chemotherapy are main treatments for this disease，but therapeutic strategy is still controversia.Whether combine radiotherapy and chemotherapy，how to combine radiotherapy and chemotherapy still have not been a consensus.For stageⅠ－Ⅱ，the combination of chemotherapy and radiotherapy has better therapeutic effects．As for stage Ⅲ－Ⅳ ENKTL，the chemotherapy is the main treatment method.L-ASP-based chemotherapy regimens treated in each period have showed good results compared with CHOP or CHOP like chemotherapy regimens.The optimal chemotherapy regimen and the way of radiotherapy combined with chemotherapy still need to be supported by more large phase Ⅲ randomized controlled trials.Selection of an optimal therapy according to proper risk stratification in ENKTL is necessary to further improve the clinical outcome.It will become a new focus about treatment for ENKTL.This review mainly focuses on the advance of radiotherapy and chemotherapy for ENKTL in order to provide reference.

References:

［1］Jaffe ES，Harris NL，Stein H，et al.World Health Organization classification of tumors：Pathology and genetics of tumours of hematopoietic and lymphoid tissues［M］.Lyon，France：IARC Press，2001：189-237.
[2]Li YX，Wang H，Jin J，et al.Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma［J］.Int J Radiat Oncol Biol Phys，2012，82：1809-1815.
[3]Koom WS，Chung EJ，Yang WI，et al.Angiocentric T-cell and NK/T-cell lymphomas：Radiotherapeutic viewpoints［J］.Int J Radiat Oncol Biol Phys，2004，59：1127-1137.
[4]Isobe K，Uno T，Tamaru J，et al.Extranodal natural killer/T-cell lymphoma，nasal type：The significance of radiotherapeutic parameters［J］.Cancer，2006，106：609-615.
[5]Dong LH，Zhang LJ，Wang WJ，et al.Sequential DICE combined with L-asparaginase chemotherapy followed by involved field radiation in newly diagnosed，stage ⅠE to ⅡE，nasal and extranodal NK/T-cell lymphoma［J］.Leuk Lymphoma，2016，57(7)：1600-1606.
[6]Li X，Cui Y，Sun Z，et al.DDGP versus SMILE in newly diagnosed advanced natural killer/T cell lymphoma：A randomized controlled，multicenter，open-label study in China［J］.Clin Cancer Res，2016，22(21)：5223-5228.
[7]Li YX，Yao BY，Wang WH，et al.Radiotherapy as primary treatment for stage ⅠE and ⅡE nasal natural killer/T-cell lymphoma［J］.J Clin Oncol，2006，24：181-189.
[8]Yang Y，Cao JZ，Lan SM，et al.Association of improved locoregional control with prolonged survival in early-stage extranodal nasal-type natural killer/T-cell lymphoma［J］.JAMA Oncol，2017，3（1）:83-91.
[9]Boros A，Michot JM，Hoang-Xuan K.Role of radiotherapy in the treatment of NK/T-cell nasal type and primary cerebral lymphomas［J］.Cancer Radiother，2016，20：535-542.
[10]Shen Q，Ma X，Hu W，et al.Intensity modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I-II natural killer/T cell lymphoma nasal type：Dosimetric and clinical results［J］.Radiation Oncology，2013，8：152.
[11]Yang Y，Zhu Y，Cao JZ，et al.Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma：Analysis from a multicenter study［J］.Blood，2015，126：1424-1432.
[12]Tse E.Nasal NK/T-cell lymphoma：RT，CT，or both［J］.Blood，2015，126：1400-1401.
[13]Kwong YL，Kim WS，Lim ST，et al.SMILE for natural killer/T-cell lymphoma：Analysis of safety and efficacy from the Asia lymphoma study group［J］.Blood，2012，120（15）：2973-2980.
[14]Deng XW，Li YX，Zhu Y，et al.Can radiation therapy be omitted in patients with early-stage NK/T-cell lymphoma who achieved complete response to chemotherapy?A multicenter analysis［J］.Int J Radiat Oncol Biol Phys，2016，96：E488.
[15]Huang L，Yuan B，Wu H，et al.Comparative study of L-asparaginase-based LOP regimen over CHOP regimen before radiotherapy for stage ⅡE extranodal nasal type NK/T cell lymphoma：A study of 2 centers［J］.Clin Lymphoma Myeloma Leuk，2017，17（3）：152-158.
[16]Pokrovsky VS.L-asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma：Systematic review and Meta-analysis［J］.Expert Rev Anticancer Ther，2017，17（8）：759-768.
[17]Yang Y，Wu J，Wu T，et al.Optimizing radiation dose for early-stage extranodal nasal-type NK/T-cell lymphoma［J］.Int J Radiat Oncol Biol Phys，2016，96（2）：S166-S167.
[18]Wang H，Li YX，Wang WH，et al.Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma［J］.Int J Radiat Oncol Biol Phys，2012，82：1115-1121.
[19]Oh D，Ahn YC，Kim SJ，et al.Concurrent chemoradiation therapy followed by consolidation chemotherapy for localized extranodal natural killer/T-Cell lymphoma，nasal type［J］.Int J Radiat Oncol Biol Phys，2015，93：677-683.
[20]Shen QW，Pan ZQ，Guo Y，et al.Radiotherapy as primary treatment for stageⅠ-Ⅱextranodal natural killer/T-cell lymphoma，nasal type：Analysis of treatment outcomes［J］.Tumor，2011，31(9)：835-840.［沈倩雯，潘自强，郭晔,等.Ⅰ-Ⅱ期鼻腔结外NK/T细胞淋巴瘤放射治疗疗效分析［J］.肿瘤,2011，31(9)：835-840.］
[21]Yamaguchi M，Kwong YL，Kim WS，et al． Phase II study of SMILE chemotherapy for newly diagnosed stage IV，relapsed，or refractory extranodal natural killer (NK)/T-cell lymphoma，nasal type：The NK-Cell Tumor Study Group study［J］.J Clin Oncol，2011，29(33)：4410－4416．
[22]Kim WS，Song SY，Ahn YC，et al.CHOP followed by involved field radiation：Is it optimal for localized nasal natural killer/T-cell lymphoma［J］?Ann Oncol，2001，12：349-352.
[23]Wang L，Wang ZH，Chen XQ，et al.First-line combination of gemcitabine，oxaliplatin，and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage ⅠE/ⅡE extranodal natural killer/T-cell lymphoma［J］.Cancer，2013，119：348-355.
[24]Wang JH，Wang H，Wang YJ，et al.Analysis of the efficacy and safety of a combined gemcitabine，oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma［J］.Oncotarget，2016，7：35412-35422.
[25]Dong LH，Zhang LJ，Wang WJ，et al.Sequential DICE combined with L-asparaginase chemotherapy followed by involved field radiation in newly diagnosed，stage ⅠE to ⅡE，nasal and extranodal NK/T-cell lymphoma［J］.Leuk Lymphoma，2016，57：1600-1606.
[26]Chauchet A，Michallet AS，Berger F，et al.Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma［J］.J Hematol Oncol，2012，5：27.
[27]Bi XW，Li YX，Fang H，et al.High-dose and extended-field intensity modulated radiation therapy for early-stage NK/T-cell lymphoma of Waldeyer's ring：Dosimetric analysis and clinical outcome［J］.Int J Radiat Oncol Biol Phys，2013，87：1086-1093.
[28]Zhang L，Jiang M，Xie L，et al.Five-year analysis from phase 2 trial of "sandwich" chemoradiotherapy in newly diagnosed，stage ⅠE to ⅡE，nasal type，extranodal natural killer/T-cell lymphoma［J］.Cancer Med，2016，5(1)：33-40.
[29]Tsai HJ，Lin SF，Chen CC，et al.Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma［J］.Eur J Haematol，2015，94：130-137.
[30]Rong QL，Li YX，Zhu Y，et al.Treatment outcome for patients with stage Ⅱ extranodal nasal-type NK/T-cell lymphoma：A multicenter study［J］.Int J Radiat Oncol Biol Phys，2016，96：E489.
[31]Yamaguchi M，Tobinai K，Oguchi M，et al.Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma：An updated analysis of the Japan clinical oncology group study JCOG0211［J］.J Clin Oncol，2012，30：4044-4046.
[32]Kim SJ，Kim K，Kim BS，et al.Phase Ⅱ trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed，stage ⅠE to ⅡE，nasal，extranodal NK/T-cell lymphoma：Consortium for improving survival of lymphoma study［J］.J Clin Oncol，2009，27：6027-6032.
[33]Kim SJ，Yang DH，Kim JS，et al.Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy，VIDL，for localized nasal extranodal NK/T cell lymphoma：CISL08-01 phase II study［J］.Ann Hematol，2014，93：1895-1901.
[34]Ke QH，Zhou SQ，Du W，et al.Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed，stage ⅠE to ⅡE，nasal，extranodal NK/T-cell lymphoma［J］.Blood Cancer J，2014，4：e267.
[35]Michot JM，Mazeron R，Danu A，et al.Concurrent etoposide，steroid，high-dose Ara-C and platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma，nasal type［J］.Eur J Cancer，2015，51：2386-2395.
[36]Lee J，Suh C，Park YH，et al.Extranodal natural killer T-cell lymphoma，nasal-type：A prognostic model from a retrospective multicenter study［J］.J Clin Oncol，2006，24：612-618.
[37]Kim SJ，Yoon DH，Jaccard A，et al.A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment：A multicentre，retrospective analysis［J］.The Lancet Oncology，2016，17(3)：389-400.
[38]Yang Y，Zhang YJ，Zhu Y，et al.Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma，nasal-type：A multicenter study［J］.Leukemia，2015，29：1571-1577.
[39]Wang L，Wang H，Wang JH，et al.Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase［J］.Oncotarget，2015，6：30317-30326.
[40]Kim SJ，Choi JY，Hyun SH，et al.For the Asia lymphoma study group.Risk stratifiation on the basis of deauville score on PET-CT and the presence of epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma，nasal type：A multicentre，retrospective analysis［J］.Lancet Haematol，2015，2(2)：e66-e74.

Memo

Memo:
安徽十二五临床医学重点专科建设基金赞助项目（编号：01Z33）
Last Update: 2017-11-30